NUVECTIS PHARMA INC (NVCT:NASDAQ)
$21.12 0.99 (4.918%)
Analysed NUVECTIS PHARMA INC (NVCT:NASDAQ) News Sources
Haisco and Nuvectis sign licensing deal for two drugs
24-06-2026
pharmaceutical-technology.com
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
26-06-2026
yahoo.com
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
30-06-2026
yahoo.com
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)
30-06-2026
advfn.com
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
08-07-2026
yahoo.com
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
14-07-2026
yahoo.com
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
19-08-2026
yahoo.com
Nuvectis Pharma To Participate in Upcoming Investor Conferences
03-09-2026
yahoo.com
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
24-09-2026
yahoo.com
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
09-10-2026
yahoo.com
What is the current price of NUVECTIS PHARMA INC (NVCT:NASDAQ)?
The current price of NUVECTIS PHARMA INC (NVCT:NASDAQ) is $21.12.
NUVECTIS PHARMA INC (NVCT:NASDAQ) absolute price change since previous trading day?
The absolute price change of NUVECTIS PHARMA INC (NVCT:NASDAQ) since the previous trading day is $0.99.
NUVECTIS PHARMA INC (NVCT:NASDAQ) percentage price change since previous trading day?
The percentage price change of NUVECTIS PHARMA INC (NVCT:NASDAQ) since the previous trading day is 4.918%.
What is the most recent average sentiment score for NUVECTIS PHARMA INC (NVCT:NASDAQ)?
The most recent average sentiment score for NUVECTIS PHARMA INC (NVCT:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for NUVECTIS PHARMA INC (NVCT:NASDAQ)?
The most recent sentiment for NUVECTIS PHARMA INC (NVCT:NASDAQ) is .
SEC-8K** Filing Available For NUVECTIS PHARMA INC (NVCT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.